Description
C-erbB-3, a glycoprotein of 160 kD, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-2 (HER2/neu), c-erbB-4 and the epidermal growth factor receptor (EGFR, c-erbB-1). Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-3 is expressed in tissues from the digestive, urinary and respiratory tracts, the circulatory system, and female and male reproductive organs. c-erb B-3 is undetectable in hematopoietic tissue and cell lines derived from hematopoietic tumors. Cellular localization has been described as cytoplasmic and/or membrane, and nuclear. The level and pattern of c-erbB-3 expression varies widely in both normal and tumor tissues. Clone RTJ.1 recognizes an epitope in the cytoplasmic domain of the human c-erbB-3 protein. It does not react with the EGF receptor or c-erbB-2. A synthetic peptide (referred to as 49.3) from the cytoplasmic domain of human c-erbB-3 protein was used as immunogen. RTJ.1 identifies a 160 kD band corresponding to c-erbB-3 by western blot analysis and immunoprecipitation. RTJ.1 may also react with two additional, unidentified higher molecular weight bands by immunoprecipitation and western blot analysis. These bands are likely to be non-specific, as they were not detected with a polyclonal antibody raised against the same immunogen. Because two additional bands were observed, the specificity of RTJ.1 for immunohistochemistry was analyzed by comparing staining results to those obtained using three polyclonal antibodies also raised against 49.3. Identical staining results were obtained using RTJ.1 and all three polyclonal antibodies. These results validated the use of RTJ.1 for immunohistochemical analysis of c-erbB-3.
Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
1. An isotype control should be used at the same concentration as the antibody of interest.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
4. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
5. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
